Innogenia Therapeutics Lists on KOSDAQ... Shares Open Down 3.41% on First Day, TIE2-Based Drug Development Technology Put to the Test
Innogenia Therapeutics listed on the KOSDAQ market on the 18th. As of 9 a.m. on the 18th, its first day of trading, the stock price stands at 11,590 won, down 3.41%. As a bio company distinguished by its proprietary TIE2-based technology that selectively targets pathological vascular endothelial cel

Innogenia Therapeutics listed on the KOSDAQ market on the 18th. As of 9 a.m. on the 18th, its first day of trading, the stock price stands at 11,590 won, down 3.41%. As a bio company distinguished by its proprietary TIE2-based technology that selectively targets pathological vascular endothelial cells, its post-listing market evaluation is drawing attention. Its industry classification is natural science and engineering research and development.
Offering Price at 12,000 Won... Demand Forecast Competition Ratio of 50.4 to 1
The final offering price for this listing was set at 12,000 won, the bottom of the desired price band (12,000 to 14,500 won). The number of shares offered is 5 million, with a total offering amount of 60 billion won. The earlier demand forecast conducted for institutional investors recorded a competition ratio of 50.4 to 1. The general subscription allocation was between 1.25 million and 1.5 million shares, with Samsung Securities serving as the lead underwriter.
Core Competitiveness Lies in 'TIE-body' Platform Technology... TIE2 Receptor Activation
The company's core competitiveness is its 'TIE-body' platform technology targeting pathological vascular endothelial cells. Vascular endothelial cells form the innermost layer of blood vessels and are involved in vascular stability, permeability, and inflammatory responses. Innogenia Therapeutics is researching therapeutics that target abnormal vascular endothelial cells occurring in various diseases, aiming to enhance cell survival while reducing vascular leakage and inflammation and restoring a healthy endothelial cell layer.
The key target of TIE-body is the TIE2 receptor tyrosine kinase located on the surface of vascular endothelial cells. The antibodies the company develops work through a 'TIE2 agonistic antibody' mechanism, selectively binding to specific sites of TIE2 and then activating the receptor. The company states that it analyzed the structures of the antibody and TIE2 to confirm its proprietary mechanism of action and differentiated mode of working. Related research findings were published in Nature Communications in 2021, following antigen-antibody structural analysis and biochemical and cell biological studies.
The underlying technology originated from research teams at KAIST and the Institute for Basic Science (IBS). Innogenia Therapeutics says it secured exclusive worldwide development and commercialization rights to the technology, then refined and optimized the core technology to develop it into drug candidates suitable for clinical development.
Pipeline: Treatments for Ocular Retinal Diseases, Glaucoma, and Chronic Kidney Disease
Its major pipeline includes IGT-427 for ocular retinal diseases, IGT-302 for glaucoma, and IGT-303 for chronic kidney disease. Rather than limiting itself to a single disease, the company's strategy is to expand its development scope across various diseases using vascular endothelial cells and TIE2 as a common axis.
Post-Listing Points to Watch and Investment Considerations
After the listing, the key point to watch will be how much competitiveness the proprietary TIE2 technology can demonstrate in actual clinical development. It is also worth noting that the value of a bio company can vary significantly depending on the progress of clinical trials, technology transfers, R&D costs, and the pace of cash burn.
In particular, there is no guarantee that the efficacy confirmed in the research stage of drug candidates will be reproduced identically in actual clinical trials, and there is also the possibility of clinical delays, suspension, or failure to obtain approval. The offering price does not guarantee a floor for the stock price after listing, so investors should also be mindful of the high volatility typical of newly listed stocks.
[Newly listed stocks and bio stocks can experience greatly expanded price volatility in the early listing period depending on supply and demand, clinical trial results, technology transfers, and R&D schedules. The offering price and the post-listing market price are separate matters, and investment decisions and responsibilities rest with the investor. This article was written with AI assistance.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.



![[Featured Stocks] MLCC-related stocks fall across the board... Amotech plunges 17%, Samsung Electro-Mechanics drops below 800,000 won](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F10%2F618733%2F32ad1c6b0cafe51d%2Fvariants%2Fhero.webp&w=1920&q=75)